Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
AstraZeneca
Harvard Business School
Merck
Boehringer Ingelheim

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,105,530

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,105,530
Title:Pyrimidineamines as angiogenesis modulators
Abstract:Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
Inventor(s): Boloor; Amogh (Lubbock, TX), Cheung; Mui (Durham, NC), Davis; Ronda (Durham, NC), Harris; Philip Anthony (Durham, NC), Hinkle; Kevin (Durham, NC), Mook, Jr.; Robert Anthony (Durham, NC), Stafford; Jeffery Alan (San Diego, CA), Veal; James Marvin (Durham, NC)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/451,305
Patent Claims: 1. A compound of the formula: ##STR00125## or a salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula: ##STR00126## or a salt thereof, and one or more pharmaceutically acceptable carriers, diluents and excipients.

3. The pharmaceutical composition of claim 2, further comprising at least one additional agent that is an anti-neoplastic agent.

4. The pharmaceutical composition of claim 2, further comprising an additional ggent that inhibits angiogenesis.

5. A method of treating a disorder in a mammal, said disorder being characterized by inaporooriate angiogenesis, wherein the disdrder is a proliferative retinopathy, comprising administering to said mammal a therapeutically effective amount of a compound of the formula: ##STR00127## or a salt thereof.

6. A compound of the formula: ##STR00128## or a salt thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula: ##STR00129## or a salt thereof, and one or more pharmaceutically acceptable carriers, diluents and excipients.

8. The pharmaceutical composition of claim 7, further comprising at least one additional agent that is an anti-neopiastic agent.

9. The pharmaceutical composition of claim 7, further comprising an additional agent that inhibits angiogenesis.

10. A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, wherein the disorder is a proliferative retinopathy, comprising administering to said mammal a therapeutically effective amount of a compound of the formula: ##STR00130## or a salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.